Analyst on AbbVie (ABBV): ‘Stay Long’

Core Viewpoint - AbbVie Inc. (NYSE:ABBV) is a prominent stock being discussed during the latest earnings season, with a notable increase in share price of 21% year-to-date [1]. Group 1: Investment Recommendations - Jason Snipe, Founder and Chief Investment Officer of Odyssey Capital Advisors, has recommended investors to "stay long" on AbbVie Inc. [1]. - Carillon Eagle Growth & Income Fund noted that AbbVie Inc.'s shares were a detractor for their portfolio in Q2 2025, primarily due to the underperformance of the broader biopharmaceutical industry [2]. Group 2: Market Context - The biopharmaceutical industry is currently facing pressures from policy threats related to tariffs and drug pricing proposals from the Trump administration, impacting AbbVie Inc.'s performance [2]. - Despite the challenges, there is an acknowledgment of AbbVie Inc.'s potential as an investment, although some believe that AI stocks may offer greater promise for higher returns with limited downside risk [2].